DALE GORDON
CHIEF EXECUTIVE OFFICER
Gordon succeeded founders Jon Wolff and Jim Hagstrom in carrying the scientific legacy of the company forward with an expanded focus on enabling both the research and biopharmaceutical manufacturing markets, specifically in the cell and gene therapy industry. Gordon brought more than three decades of global leadership experience in life sciences to Mirus, most recently as CEO of Gemini Biosciences. Before Gemini, Gordon held leadership roles at GE Life Sciences (Now Cytiva) and Merck Millipore.
Under Gordon’s guidance, Mirus Bio has become a trusted name in cell and gene therapy, developing innovative technologies that enable efficient and effective delivery of genetic material into cells. His strategic vision and commitment to scientific excellence have positioned Mirus Bio as a frontrunner in the cell and gene therapy industry. Gordon’s passion for improving human health through advanced therapies has been the driving force behind Mirus Bio’s achievements. He has fostered a collaborative, dynamic work culture that encourages innovation and empowers employees to push boundaries.
Gordon holds a Microbiology and Cell Science degree from the University of Florida. His commitment to advancing gene therapy and improving patient outcomes has earned him respect from the Mirus Bio team. As the CEO of Mirus Bio, Gordon remains dedicated to leading the company toward new frontiers in gene delivery technology. His unwavering commitment to excellence and innovation ensures that Mirus Bio will continue to contribute significantly to the field and revolutionize the treatment of genetic diseases.